contact us krjpencn

뉴스현황

뉴스현황

현재 위치: > 뉴스현황

  • 11
    26

    2021

    3 Bispecific Antibody Therapeutic Drugs assisted by Medicilon were approved within 10 days

    In just 10 days, Medicilon helped 3 bispecific antibody therapeutic drugs to be approved! This is another achievement of the high-quality construction of Medicilon's one-stop preclinical medicine R&D service platform.  Behind these remarkable achievements, it is inseparable from the efforts and dedication of every researcher in Medicilon.


  • 11
    24

    2021

    Shanghai International Service Trade Demonstration Project

    Shanghai Medicilon Inc. (Medicilon)’s " Safety Evaluation of Biotechnology Drugs and Non-Human Primates Service Platform" and "Professional Technical Service Platform for Isotope Drug Metabolism Research" were selected as Shanghai International Service Trade Demonstration project.  It is reported that only 13 projects in Shanghai have been selected as "Shanghai International Service Trade Demonstration Project".

  • 11
    24

    2021

    Medicilon is included in the MSCI China Index

    Shanghai Medicilon Inc. (stock code: 688202.SH) has been added to the MSCI China A-Share Index by virtue of its stable performance on the Sci-tech Innovation Board since its listing. This will take effect after the market closes on November 30, 2021.

  • 11
    24

    2021

    2021 Super CEO of the Pharmaceutical and Health Industry

    Dr. Chunlin Chen, founder and CEO of Shanghai Medicilon Inc. (Medicilon), stood out from the incumbent CEOs of more than 6,000 Chinese companies and was awarded the “2021 Super CEO of the Pharmaceutical and Health Industry”.

  • 10
    18

    2021

    Zhangjiang AI New Drug R&D Alliance Establishment Conference was successfully held

    On October 12, the sub-forum of International Biopharm Industry Week Shanghai 2012 - Zhangjiang Life Science International Innovation Summit hosted by Shanghai Medicilon Inc. (Medicilon), Internationalization Trend of Chinese Pharmaceutical Companies and AI R&D Innovation Forum and Zhangjiang AI New Drug R&D Alliance Establishment Conference was successfully held in Shanghai.